2nd Covalent Drug Discovery and Development Summit

Uniting Large Pharma, Innovative Biotech and Leading Academics to Eliminate the Boundaries of Druggability with Novel Covalent Drugs

With continued advancements in screening platforms and proteomics, the covalency renaissance continues as biopharma race to unlock hard-to-target proteins across oncology, immunology and CNS. We are witnessing this industry make great strides in utilizing novel covalent modalities and elucidating novel warheads to target amino acids beyond cysteine. However, developing covalent drugs remains no easy feat, as knowledge gaps persist in balancing reactivity and selectivity, de-risking the ligandability of alternative residues, and tackling PKPD disconnects and efficiency bottlenecks to successfully develop potent covalent drugs for unmet clinical need.

The 2nd Covalent Drug Discovery and Development Summit returns as the central hub dedicated to every aspect of covalency from discovery to translation and clinical development, equipping 100+ global covalency leaders with the means to expand the druggable proteome.

URLs:
Website: https://go.evvnt.com/2537785-0?pid=176
Tickets: https://go.evvnt.com/2537785-2?pid=176
Brochure: https://go.evvnt.com/2537785-3?pid=176

Time: 9:00 AM - 5:00 PM

Prices:
Drug Developer Pricing - Conference + 2 Workshops: USD 4197.00,
Drug Developer Pricing - Conference + 1 Workshops: USD 3638.00,
Drug Developer Pricing - Conference Only: USD 2999.00,
Academic Pricing- Conference + 2 Workshops: USD 3597.00,
Academic Pricing- Conference + 1 Workshops: USD 3138.00,
Academic Pricing- Conference Only: USD 2599.00,
Vendor Pricing- Conference + 2 Workshops: USD 5097.00,
Vendor Pricing- Conference + 1 Workshops: USD 4432.00,
Vendor Pricing- Conference Only: USD 3699.00

Speakers: Adam Cotton -Associate - Novartis Venture Fund, Andrea Zuhl -Vice President, Chemical Biology and Proteomics - HYKU Biosciences, Brent Martin -Vice President and Head of Chemical Biology - Scorpion Therapeutics, Brett Babin -Principal Scientist - Genentech, David Weinstein - Vice President and Head of Chemistry - Vividion Therapeutics, Doug Johnson -Senior Director - Biogen, George Naumov -Chief Operating Officer and Head of Business Development - RS Oncology Ltd, Iván Cornella - Chief Scientific Officer -Covant Therapeutics, Jaimeen Majmudar - Senior Principal Scientist - Pfizer, Jamie Rice - Senior Director and Head of Discovery Biology - Covant Therapeutics, Jin Wang - Professor and Director of Centre for NextGen Therapeutics - Baylor College of Medicine, Ken Hsu - Associate Professor - University of Texas at Austin, Lynn McGregor -Senior Principal Scientist - Novartis AG, Mark Springel - Senior Associate - Vida Ventures LLC, Maurizio Pellecchia - Professor of Biomedical Sciences, Director Center for Molecular and Translational Medicine - University of California Riverside and Armida Labs, Micah Niphakis - Director of Chemical Biology - Lundbeck, Monica Schenone - Senior Director and Head of Chemical Biology and Proteomics - Pfizer, Rhamy Zeid - Vice President and Head of Biology - Nexo Therapeutics, Sebastian Essig - Director Chemical Biology - Bayer, Stefan Harry - Postdoctoral Fellow - Harvard Medical School, Takeshi Sagara - Managing Director, Clinical Development and Medical Affairs, Discovery and Preclinical Research - Taiho Pharmaceutical, Xiang Yi - Principal scientist - Amgen Inc.